Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2025
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family of devices, Photrexa for keratoconus, and the recently commercialized iDose TR intracameral implant.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $106,664 | $85,622 |
| Gross Profit | $82,348 | $65,364 |
| Gross Margin | 77% | 76% |
| Operating Expenses | $103,026 | $104,430 |
| Loss from Operations | $(20,678) | $(39,066) |
| Net Loss | $(18,146) | $(40,838) |
| Net Loss Per Share (Basic & Diluted) | $(0.32) | $(0.82) |
Liquidity and Balance Sheet Highlights (in thousands)
- Cash and Cash Equivalents: $114,252 (March 31, 2025) vs. $169,626 (Dec 31, 2024)
- Short-term Investments: $184,444 (March 31, 2025) vs. $149,289 (Dec 31, 2024)
- Total Current Assets: $444,544
- Total Current Liabilities: $68,529
- Working Capital: $376,015
- Accumulated Deficit: $(763,585)
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% year-over-year to $106.7 million. This was driven primarily by a 41% increase in U.S. glaucoma sales ($59.1M), attributed to the commercial launch of iDose TR, partially offset by slightly lower volumes of the iStent family. International glaucoma sales grew 15% to $29.0M.
- Profitability Improvement: Net loss narrowed significantly by 56% to $18.1 million, compared to $40.8 million in Q1 2024. The operating loss decreased by 47% to $20.7 million.
- Expense Reduction: Total operating expenses decreased slightly by 1% to $103.0 million. This reduction was primarily due to the absence of $11.7 million in acquired in-process research and development (IPR&D) expenses recorded in Q1 2024 related to an asset acquisition.
- Non-Operating Income: Non-operating income turned positive at $2.9 million (vs. expense of $1.4 million in Q1 2024), driven by a $2.3 million decrease in interest expense following the redemption of Convertible Notes in late 2024 and favorable foreign currency adjustments.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- iDose TR Commercialization: Management anticipates increased utilization of iDose TR as reimbursement processes become more consistent. The product received a permanent J-code (J7355) effective July 1, 2024.
- Reimbursement Environment: Finalization of Local Coverage Determinations (LCDs) by Medicare Administrative Contractors (MACs) in late 2024 has disrupted traditional ordering patterns for iStent family products used in conjunction with cataract surgery. Management notes that CMS physician fee payment rate decreases may have reduced U.S. glaucoma sales volumes.
- Competitive Landscape: The company faces increasing competition in the U.S. and globally. The royalty income from the Ivantis settlement expired on April 26, 2025.
- Capital Expenditures: Capital expenditures are expected to be higher in 2025 due to manufacturing upgrades and R&D equipment. A new 200,000 sq. ft. R&D and manufacturing facility in Huntsville, Alabama, is planned with construction expected to begin in 2026.
Risks and Contingencies
- Commercial Success of iDose TR: Failure to achieve commercial success for iDose TR due to physician adoption, reimbursement, or manufacturing issues could materially impact the business.
- Supply Chain and Tariffs: Ongoing inflation, supply shortages, and new U.S. tariffs on imports from Canada, Mexico, and China pose risks to cost structures and supply continuity.
- Regulatory and Reimbursement: Changes in healthcare legislation, pricing programs (e.g., Medicaid Drug Rebate Program), and reimbursement rates by MACs and CMS remain significant uncertainties.
- Profitability: The company has an accumulated deficit of $763.6 million and may not reach sustained profitability. Future funding may be required.
Key Facts for Investor Verification
- iDose TR Adoption Rates: Verify the actual uptake of iDose TR in Q2 2025 to confirm if the anticipated increase in utilization materializes following the permanent J-code assignment.
- Reimbursement Impact on iStent: Monitor the extent to which the finalized MAC LCDs and fee rate changes continue to suppress volumes of the iStent family when used with cataract surgery.
- Working Capital Trends: Track accounts receivable days sales outstanding (DSO), which increased due to extended payment terms for iDose TR, to ensure cash collection remains efficient.
- Subsequent Event: Note the April 4, 2025, purchase of a 40,000 sq. ft. building in Aliso Viejo for $16.6 million, which impacts future cash flow and capital allocation.
- Debt Status: Confirm the company remains debt-free regarding Convertible Notes (fully redeemed in Dec 2024) and monitor future financing needs given the accumulated deficit.